Resolution of novel human papillomavirus- induced warts after HPV vaccination

Emerging Infectious Diseases

Volumn 20, Issue 1, 2014, Pages 142-145

  Silling, Steffi ^a   Wieland, Ulrike ^a   Werner, Marko ^a   Pfister, Herbert ^a   Potthoff, Anja ^b   Kreuter, Alexander ^b,c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c St Elisabeth Hospital   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; FLUOROURACIL; HEMOGLOBIN BETA CHAIN; IMIQUIMOD; PODOPHYLLOTOXIN; SALICYLIC ACID; WART VIRUS VACCINE;

ACANTHOSIS; ARTICLE; CAUTERIZATION; CD4 CD8 RATIO; CLINICAL ARTICLE; CONTROLLED STUDY; CRYOSURGERY; FEMALE; GLOBIN GENE; HUMAN; HUMAN TISSUE; IMMUNE DEFICIENCY; IMMUNOCOMPETENT CELL; LOW LEVEL LASER THERAPY; MALE; NUCLEOTIDE SEQUENCE; PARAKERATOSIS; POLYMERASE CHAIN REACTION; SKIN BIOPSY; VERRUCA VULGARIS; VIRUS LOAD; WART VIRUS;

HPV; HPV VACCINATION; HPVXS2; HUMAN PAPILLOMAVIRUS; IMMUNOSUPPRESSED; NOVEL HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRUS; QUADRIVALENT HPV VACCINE; VACCINATION; VIRUSES; WARTS;

ADULT; ALPHAPAPILLOMAVIRUS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAPSID PROTEINS; DNA, VIRAL; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MOLECULAR SEQUENCE DATA; PAPILLOMAVIRUS VACCINES; PHYLOGENY; SKIN; VACCINATION; WARTS;

EID: 84890932700     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid2001.130999     Document Type: Article

References (15)

1. Bernard HU, Burk RD, Chen Z, van Doorslaer K, Hausen H, de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology. 2010;401:70-9. http://dx.doi.org/10.1016/j. virol.2010.02.002
2. Leiding JW, Holland SM. Warts and all: human papillomavirus in primary immunodeficiencies. J Allergy Clin Immunol. 2012;130:1030-48. http://dx.doi.org/10.1016/j.jaci.2012.07.049
3. Sri JC, Dubina MI, Kao GF, Rady PL, Tyring SK, Gaspari AA. Generalized verrucosis: a review of the associated diseases, evaluation, and treatments. J Am Acad Dermatol. 2012;66:292-311. http://dx.doi.org/10.1016/j.jaad.2010.12.011
4. Venugopal SS, Murrell DF. Recalcitrant cutaneous warts treated with recombinant quadrivalent human papillomavirus vaccine (types 6, 11, 16, and 18) in a developmentally delayed, 31-year-old white man. Arch Dermatol. 2010;146:475-7. http://dx.doi.org/10.1001/ archdermatol.2010.71
5. Kreuter A, Waterboer T, Wieland U. Regression of cutaneous warts in a patient with WILD syndrome following recombinant quadrivalent human papillomavirus vaccination. Arch Dermatol. 2010;146:1196-7. http://dx.doi.org/10.1001/archdermatol.2010.290
6. Berkhout RJ, Bouwes Bavinck JN, ter Schegget J. Persistence of human papillomavirus DNA in benign and (pre)malignant skin lesions from renal transplant recipients. J Clin Microbiol. 2000;38:2087-96.
7. Wieland U, Ritzkowsky A, Stoltidis M, Weissenborn S, Stark S, Ploner M, et al. Papillomavirus DNA in basal cell carcinomas of immunocompetent patients: an accidental association? J Invest Dermatol. 2000;115:124-8. http://dx.doi.org/10.1046/j.1523-1747.2000.00015.x
8. Gross G, Pfister H, Hagedorn M, Gissmann L. Correlation between human papillomavirus (HPV) type and histology of warts. J Invest Dermatol. 1982;78:160-4. http://dx.doi.org/10.1111/1523-1747. ep12506324
9. van Duin M, Snijders PJ, Schrijnemakers HF, Voorhorst FJ, Rozendaal L, Nobbenhuis MA, et al. Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/ III and viral clearance. Int J Cancer. 2002;98:590-5. http://dx.doi. org/10.1002/ijc.10232
10. Wieland U, Silling S, Scola N, Potthoff A, Gambichler T, Brockmeyer NH, et al. Merkel cell polyomavirus infection in HIV-positive men. Arch Dermatol. 2011;147:401-6. http://dx.doi. org/10.1001/archdermatol.2011.42
11. Köhler A, Meyer T, Stockfleth E, Nindl I. High viral load of human wart-associated papillomaviruses (PV) but not beta-PV in cutaneous warts independent of immunosuppression. Br J Dermatol. 2009;161:528-35. http://dx.doi.org/10.1111/j.1365-2133.2009.09297.x
12. Landis MN, Lookingbill DP, Sluzevich JC. Recalcitrant plantar warts treated with recombinant quadrivalent human papillomavirus vaccine. J Am Acad Dermatol. 2012;67:e73-4. http://dx.doi. org/10.1016/j.jaad.2011.08.022
13. Daniel BS, Murrell DF. Complete resolution of chronic multiple verruca vulgaris treated with quadrivalent human papillomavirus vaccine. JAMA Dermatol. 2013;149:370-2. http://dx.doi. org/10.1001/jamadermatol.2013.1463
14. Kreuter A, Wieland U. Lack of efficacy in treating condyloma acuminata and preventing recurrences with the recombinant quadrivalent human papillomavirus vaccine in a case series of immunocompetent patients. J Am Acad Dermatol. 2013;68:179-80. http://dx.doi.org/10.1016/j.jaad.2011.11.970
15. Handisurya A, Schellenbacher C, Reininger B, Koszik F, Vyhnanek P, Heitger A, et al. A quadrivalent HPV vaccine induces humoral and cellular immune responses in WHIM immunodeficiency syndrome. Vaccine. 2010;28:4837-41. http://dx.doi.org/10.1016/ j.vaccine.2010.04.057